Gefitinib was developed as an EGFR-TK inhibitor and remarkably reduces tumour growth in many lung cancer patients; however, a drug-resistant cancer cell population emerges after treatment, resulting in recurrence of the disease. The gene discussed is EGFR; the disease is cancer.